Search Result

Results for "

22Rv1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (2) Aldose Reductase (1) Androgen Receptor (11) Apoptosis (11) Bcl-2 Family (2) c-Myc (1) Caspase (2) CD3 (1) CDK (2) COX (2) CXCR (1) DNA Stain (1) E3 Ligase Ligand-Linker Conjugates (1) Epigenetic Reader Domain (10) Fatty Acid Synthase (FASN) (1) Ferroptosis (2) Fluorescent Dye (1) Glucocorticoid Receptor (1) HCV (2) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (5) Histone Demethylase (3) Histone Methyltransferase (1) IAP (1) IFNAR (1) Interleukin Related (1) JAK (1) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (1) MNK (1) PROTAC Linkers (1) PROTACs (11) PSMA (2) Reactive Oxygen Species (1) ROR (3) SARS-CoV (1) Sirtuin (1) STAT (1)
By Research Areas:	Cancer (63) Cardiovascular Disease (2) Endocrinology (2) Infection (2) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (3)

By Targets:

Adrenergic Receptor (2)

Aldose Reductase (1)

Androgen Receptor (11)

Apoptosis (11)

Bcl-2 Family (2)

c-Myc (1)

Caspase (2)

CD3 (1)

CDK (2)

COX (2)

CXCR (1)

DNA Stain (1)

E3 Ligase Ligand-Linker Conjugates (1)

Epigenetic Reader Domain (10)

Fatty Acid Synthase (FASN) (1)

Ferroptosis (2)

Fluorescent Dye (1)

Glucocorticoid Receptor (1)

HCV (2)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Acetyltransferase (5)

Histone Demethylase (3)

Histone Methyltransferase (1)

IAP (1)

IFNAR (1)

Interleukin Related (1)

JAK (1)

Ligands for E3 Ligase (2)

Ligands for Target Protein for PROTAC (1)

MDM-2/p53 (1)

MNK (1)

PROTAC Linkers (1)

PROTACs (11)

PSMA (2)

Reactive Oxygen Species (1)

ROR (3)

SARS-CoV (1)

Sirtuin (1)

STAT (1)

By Research Areas:

Cancer (63)

Cardiovascular Disease (2)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (2)

Metabolic Disease (2)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149495

CP-07	PROTACs CDK	Cancer
CP-07 is a potent and selective PROTACCDK9 degrader (DC₅₀: 43 nM). CP-07 inhibits 22RV1 cell proliferation (IC₅₀: 62 nM) and colony formation by down-regulating Mcl-1 and c-Myc. CP-07 inhibits 22RV1 xenograft tumor growth. CP-07 can be used for research of prostate cancer .

HY-163510

AR/AR-V7-IN-1	Androgen Receptor	Cancer
AR/AR-V7-IN-1 (Compound 20i) is an AR/ARV7 inhibitor (IC₅₀ = 172.85 nM). AR/AR-V7-IN-1 potently inhibits cell growth with IC₅₀ values of 4.87 and 2.07 μM in the LNCaP and 22RV1 cell lines, respectively. AR/AR-V7-IN-1 exhibits effective tumor growth inhibition in the 22RV1 xenograft study. AR/AR-V7-IN-1 can be used for the research of prostate cancer .

HY-143235

BRD4 Inhibitor-15	Epigenetic Reader Domain Apoptosis Bcl-2 Family Caspase c-Myc	Cancer
BRD4 Inhibitor-15 (compound 13) is a potent BRD4 inhibitor, with an IC₅₀ of 18 nM. BRD4 Inhibitor-15 induces apoptosis of 22RV1 cells by regulating Bcl-2/Bax proteins and activating caspase-3 signaling pathway. BRD4 Inhibitor-15 down-regulates the c-Myc level in 22RV1 cells. BRD4 Inhibitor-15 can be used for prostate cancer research .

HY-150268

BET-IN-16	Epigenetic Reader Domain	Cancer
BET-IN-16 (Comp I) is a BET inhibitor. BET-IN-16 shows anticancer activity. BET-IN-16 inhibits prostate cancer cell growth, with IC₅₀ values of 0.043 and 0.034 μM against LNCaP and 22Rv1 cells, respectively .

HY-163281

FSY-OSO2F	Fluorescent Dye	Cancer
FSY-OSO2F shows an uptake in MCF-7 cells through the regulation of L-Tyr, ASC, and ASC2 transporters. FSY-OSO2F can be used as a PET tracer, when labeled with ¹⁸F, and exhibits good uptake and good contrast in MCF-7 and 22Rv1 subcutaneous tumors .

HY-149914

WCA-814	Androgen Receptor	Cancer
WCA-814 is an androgen receptor (AR) antagonist-Hsp90 inhibitor conjugate. WCA-814 induces the degradation of full-length and AR-V7. WCA-814 has cytotoxic effect in prostatic cancer cells (IC₅₀: 171.2 nM, 26.5 nM for LNCaP, 22Rv1 cell) .

HY-169078

ML234	Histone Methyltransferase	Cancer
ML234 is a dual inhibitor against EZH2/LSD1 with IC₅₀ values of 0.09 and 0.12 μM, respectively. ML234 displays an excellent antiproliferative capacity against prostate cancer cell lines LNCAP, PC3 and 22RV1. ML234 suppresses the tumor growth in the 22RV1 xenograft mouse model. ML234 is promising for research of anticancer agents in prostate cancer .

HY-P10625

SHLP-6	Apoptosis	Metabolic Disease Cancer
SHLP-6 is a mitochondrial-derived peptide, a biologically active microprotein encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP6 increases apoptosis in insulinoma cells NIT1 and human prostate cancer cell 22Rv1. SHLP6 can be used in the study of diabetes and cancer .

HY-142772

Y08284	Epigenetic Reader Domain	Cancer
Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity .

HY-158432

GT-653	Histone Demethylase PROTACs	Cancer
GT-653 is a PROTAC degrader for lysine-specific demethylase 5B (KDM5B). GT-653 degrades 68.35% KDM5B at 10 μM in a ubiquitin proteasome-dependent manner, upregulates H3K4me3 levels, and activates the type-I interferon signaling pathway in prostate cancer cells 22RV1. (Pink: KDM5B ligand (HY-158433); Black: Linker (HY-W004896); Blue: E3 ligase ligand (HY-103596))

HY-158113

CBPD-409	Histone Acetyltransferase PROTACs	Cancer
CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC₅₀ of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC₅₀s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .

HY-121588

IMTPPE	Adrenergic Receptor	Cancer
IMTPPE is an inhibitor of the androgen receptor (AR) in C4-2 prostate cancer cells, inhibiting its transcriptional activity and protein levels. IMTPPE inhibited the proliferation of AR-positive prostate cancer cells but had no effect on AR-negative prostate cancer cells. IMTPPE also inhibited the growth of enzalutamide-resistant 22Rv1 xenograft tumors .

HY-161769

HL435	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
HL435 is a heterobifunctional molecule that degrades BRD4 by linking to JQ1, with DC₅₀ of 11.9 nM and 21.9 nM, in MDA-MB-231 and MCF-7 cells, respectively. HL435 inhibits the proliferation of MDA-MB-231, MCF-7, 22Rv1 and A549, arrests the cell cycle and induces apoptosis. HL435 exhibits antitumor activity in mouse model. (Pink: ligand for target protein JQ-1 (HY-78695); Black: linker (HY-W004640); blue: ligand for E3 ligase HL389 (HY-161770))

HY-133045

VHL Ligand 8	Ligands for E3 Ligase	Cancer
VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM .

HY-117136

AN-7	HDAC Caspase Bcl-2 Family	Cancer
AN-7 is an orally active histone deacetylase (HDAC) inhibitor that induces histone hyperacetylation and differentiation in vitro and in vivo, and inhibits the proliferation of human prostate 22Rv1 cancer cells. AN-7 can increase the expression of the pro-apoptotic protein Bax, reduce the expression of the anti-apoptotic protein Bcl-2, and promote apoptosis by activating caspase-3, and can be used in the study of prostate cancer .

HY-133020

ARD-266	PROTACs Androgen Receptor	Cancer
ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM . ARD-266 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145479

PROTAC AR-V7 degrader-1	PROTACs Androgen Receptor	Cancer
PROTAC AR-V7 degrader-1 (Compound 6) is a potent, orally bioavailable and selective AR-V7 degrader with the DC₅₀ of 0.32 µM by recruiting VHL E3 ligase to Androgen receptor (AR) DNA binding domain (DBD) binder. PROTAC AR-V7 degrader-1 exhibits activity against 22Rv1 cell-line expressing AR-V7 with the EC₅₀ of 0.88 µM .

HY-P10622

SHLP-3	Apoptosis Reactive Oxygen Species	Metabolic Disease Cancer
SHLP-3 is a mitochondrial derived peptide encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-3 increases cell viability and reduces apoptosis in insulinoma NIT-1β cells and human prostate cancer 22Rv1 cells. SHLP-3 increases mitochondrial function and exerts cytoprotective effects by increasing mitochondrial oxygen consumption rate (OCR), cellular ATP and reducing the ability to produce ROS. SHLP-3 can be used in the study of diabetes and cancer .

HY-163938

PROTAC erf3a Degrader-1	PROTACs	Cancer
PROTAC erf3a Degrader-1 (Compound C63) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-1 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-1 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: CRBN ligand (HY-41547)) .

HY-164373

SC428	Androgen Receptor Apoptosis	Cancer
SC428 is an androgen receptor (AR) inhibitor that targets the N-terminal domain. SC428 potently decrease the transactivation of (AR)-V7, (AR)v567es, as well as full-length ( AR ) (AR-FL) and its LBD mutants, substantially. SC428 inhibits androgen-stimulated (AR)-FL nuclear translocation, chromatin binding, and (AR) -regulated gene transcription. SC428 inhibits the proliferation of tumor cells in vitro. SC428 inhibits tumor cell growth by inducing apoptosis in mice transplanted with 22RV1 .

HY-133044

Boc-Pip-alkyne-Ph-COOH	PROTAC Linkers	Cancer
Boc-Pip-alkyne-Ph-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-Pip-alkyne-Ph-COOH can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 effectively induces degradation of androgen receptor (AR) protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM . Boc-Pip-alkyne-Ph-COOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163938A

PROTAC erf3a Degrader-2	PROTACs	Cancer
PROTAC erf3a Degrader-2 (Compound C59) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-2 inhibits protein expression of SRD5A3 and GSPT1(eRF3a). PROTAC erf3a Degrader-2 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-2 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: E3 ligase ligand (HY-W763812)) .

HY-160777

VNPP433-3β Galeterone 3β-imidazole	Androgen Receptor MNK	Cancer
VNPP433-3β is a molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β inhibits proliferation of cancer cell LNCaP, C4-2B and CWR22Rv1 with GI₅₀ of 0.2, 0.3 and 0.31 μM. VNPP433-3β exhibits good pharmacokinetic characters in CD-1 mouse and inhibits tumor growth in the CWR22Rv1 xenograft mouse model .

HY-121522

SD-70	Histone Demethylase	Cancer
SD-70 is an inhibitor for histone demethylase JMJD2C and exhibits antitumor efficacy. SD-70 inhibits viability of cancer cells CWR22Rv1 (9% cell survival at 10 μM), PC3 (14% cell survival at 2 μM) and DU145 (26% cell survival at 2 μM) .

HY-160260

EP300/CBP-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
EP300/CBP-IN-1 (compound 172) is a potent EP300/CBP inhibitor with IC₅₀s of 2.3 nM and 2.1 nM for CBP BRD and EP300 BRD, respectively. EP300/CBP-IN-1 has the inhibitory effect on the proliferation of prostate cancer CWR22RV1 cells .

HY-163611

XY039	ROR	Cancer
XY039 (compound 13e) is a RORγ inverse agonist with the IC₅₀ of 0.55 μM. XY039 induces cell apoptosis and shows antiproliferative activity in vivoand in vitro .

HY-163612

XY077	ROR Apoptosis	Cancer
XY077 (compound 14a) is a RORγ inverse agonist with the IC₅₀ of 0.004 μM. XY077 induces cell apoptosis and shows antiproliferative activity in vivoand in vitro .

HY-162412

PROTAC AR/AR-V7 degrader-1	PROTACs Adrenergic Receptor Apoptosis	Cancer
PROTAC AR/AR-V7 degrader-1 (27c) is a PROTAC-based and dual AR, AR-V7 degrader, with DC₅₀ values of 2.67 and 2.64 μM for AR and AR-V7, respectively. PROTAC AR/AR-V7 degrader-1 (27c) induces apoptosis (Red: AR antagonist; Blue: E3 ligase ligand; Black: linker) .

HY-146573

AKR1C3-IN-6	Others	Cancer
AKR1C3-IN-6 (Compound 1) is a potent, selective AKR1C3 inhibitor with IC₅₀ values of 0.31 μM and 73.23 μM against AKR1C3 and AKR1C2, respectively. AKR1C3-IN-6 shows antitumor activity .

HY-146574

AKR1C3-IN-7	Others	Cancer
AKR1C3-IN-7 (Compound 13) is a potent, selective AKR1C3 inhibitor with an IC₅₀ of 0.19 μM. AKR1C3-IN-7 shows antitumor activity .

HY-146575

AKR1C3-IN-8	Others	Cancer
AKR1C3-IN-8 (Compound 5) is a potent, selective AKR1C3 inhibitor with an IC₅₀ of 0.069 μM. AKR1C3-IN-8 shows antitumor activity .

HY-153918

(R)-SKBG-1	Androgen Receptor	Cancer
(R)-SKBG-1 is an RNA-binding protein NONO inhibitor. (R)-SKBG-1 suppresses androgen receptor expression with IC₅₀s of 3.1 μM and 5.5 μM against AR-FL mRNA and AR-V7 mRNA, respectively .

HY-158433

KDM5B ligand 2	Ligands for Target Protein for PROTAC Histone Demethylase	Cancer
KDM5B ligand 2 is the ligand for target protein KDM5B. KDM5B ligand 2 is utilized for synthesis of KDM5B PROTAC GT-653 (HY-158432) .

HY-164005

CBP/EP300 bromodomain receptor-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/EP300 bromodomain receptor-IN-1 (Compound 10) is an inhibitor for CBP/EP300 bromodomain receptor, which binds to proteins having a bromodomain in nanomolar level .

HY-103245

Cl-4AS-1	Androgen Receptor	Cancer
Cl-4AS-1, a potent steroidal androgen receptor (AR) agonist (IC₅₀ = 12 nM), is also an inhibitor of 5α-reductase types I and II (IC50 = 6 and 10 nM, respectively) .

HY-149297

PSMA-IN-1	PSMA	Cancer
PSMA-IN-1 (compound 23) is an inhibitor of PSMA with a K_i value of 2.49 nM. PSMA-IN-1 inhibits tumor growth with high selectivity and specificity in PSMA+ xenograft models. PSMA-IN-1 is a NIR probe (λ_EX: 620 nm; λ_EM: 670 nm) used for tumor disappearance. PSMA-IN-1 can be used for research on prostate cancer .

HY-155571

MDM2/XIAP-IN-3	MDM-2/p53 IAP	Cancer
MDM2/XIAP-IN-3 (compound 3e) is a dual MDM2/XIAP inhibitor. MDM2/XIAP-IN-3 reduces MDM2 and XIAP protein levels and increases p53 expression, thereby inhibiting cancer cell growth and causing cell death .

HY-163192

W6134	ROR	Cancer
W6134 is highly potent and selective RORγ covalent inhibitor with IC₅₀ of 0.21 μM. W6134 exhibits superior activity ini nhibiting the proliferation and colony formation and inducing apoptosis. W6134 can be used for the research of cancer .

HY-162764

Androgen receptor degrader-5	Androgen Receptor	Cancer
Androgen receptor degrader-5 (compound 14k) exhibits promising properties, including superior androgen receptor degradation activity and antiproliferative activity .

HY-112659

Lin28-let-7 antagonist 1	Others	Neurological Disease Cancer
Lin28-let-7 antagonist 1 (compound 1632) is a potent antagonist of Lin28/pre-let-7 interaction. Lin28-let-7 antagonist 1 inhibits Lin28A binding to pre-let-7a-2, with an IC₅₀ of 8 μM. Lin28-let-7 antagonist 1 inhibits proliferation in human cancer cells .

HY-P99762

Obrindatamab MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-161369

CBPD-268	PROTACs Histone Acetyltransferase	Cancer
CBPD-268 is a potent and orally active CBP/p300 PROTAC degrader with an DC₅₀ value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Srtucture Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker) .

HY-142743

Y08175	Epigenetic Reader Domain	Cancer
Y08175 is a potent CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC₅₀s of 37 and 178.15 nM against CBP bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer .

HY-149927

Antitumor agent-91	Others	Cancer
Antitumor agent-91 is a cyclic phosphate ester derivative with anticancer and anti-proliferative activities. Antitumor agent-91 has potential application in human castration resistant prostate cancer and pancreatic cancer .

HY-163609

PROTAC AKR1C3 degrader-1	PROTACs Aldose Reductase	Cancer
PROTAC AKR1C3 degrader-1 (compound 5) is a potent AKR1C3 PROTAC degrader. PROTAC AKR1C3 degrader-1 decreases the protein expression of AKR1C3, AKR1C1/2, and ARv7. PROTAC AKR1C3 degrader-1 has the potential for the research of prostate cancer. (Blue:ubiquitin E3 ligase cereblon ligand (HY-A0003), Black: linker (HY-163647); Pink: AKR1C3 inhibitor (HY-163610)) .

HY-122108

Ilicicolin A LL-Z 1272-alpha	Apoptosis	Cancer
Ilicicolin A is a potent anticancer agent. Ilicicolin A induces apoptosis. Ilicicolin A inhibits cell growth and colony formation. Ilicicolin A shows antitumor activity. Ilicicolin A has the potential for the research of prostate cancer .

HY-16187

EL-102	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer .

HY-149298

PSMA-IN-2	PSMA	Cancer
PSMA-IN-2 is an inhibitor of PSMA with a K_i value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λ_EM = 1088 nm, λ_ex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice .

HY-146445

P300 bromodomain-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC₅₀ of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells .

HY-143317

XY153	Epigenetic Reader Domain	Cancer
XY153 (compound 8l) is a BD2-selective BET inhibitor and selectively binds to BRD4 BD2. XY153 binds to BRD4 BD2, BRD3 BD2 and BRD2 BD2 with IC₅₀s of 0.79, 5.31 and 5.09 nM, respectively. XY153 shows potent antiproliferative activity against multiple tumor cell lines. XY153 can be used for the research of acute myeloid leukemia (AML) and cancer .

Cat. No.	Product Name	Target	Research Area